Cellectar Biosciences Stock Performance
| CLRB Stock | USD 3.24 0.07 2.11% |
Cellectar Biosciences has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.08, which signifies a somewhat significant risk relative to the market. Cellectar Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Cellectar Biosciences is expected to follow. Cellectar Biosciences right now shows a risk of 6.54%. Please confirm Cellectar Biosciences treynor ratio, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Cellectar Biosciences will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cellectar Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, Cellectar Biosciences may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return (2.11) | Five Day Return (16.71) | Year To Date Return (6.63) | Ten Year Return (99.98) | All Time Return (100.00) |
Last Split Factor 1:30 | Dividend Date 2018-07-17 | Last Split Date 2025-06-24 |
1 | Earnings Outlook For Cellectar Biosciences | 11/12/2025 |
2 | Cellectar Biosciences GAAP EPS of -1.41 beats by 1.12 | 11/13/2025 |
3 | Cellectar Biosciences Announces Earnings Results, Beats Estimates By 0.50 EPS | 11/14/2025 |
4 | How Cellectar Biosciences Inc. stock performs in stagflation - 2025 Investor Takeaways Weekly Momentum Picks - newser.com | 11/19/2025 |
5 | Cellectar Biosciences versus Agilent Technologies Critical Analysis | 12/08/2025 |
6 | Disposition of 198 shares by Neis John of Cellectar Biosciences at 3.6969 subject to Rule 16b-3 | 12/12/2025 |
7 | Should I buy Cellectar Biosciences Inc. stock before earnings season - July 2025 Update Real-Time Market Trend Scan - DonanmHaber | 12/19/2025 |
8 | Acquisition by Jarrod Longcor of 10000 shares of Cellectar Biosciences at 5.25 subject to Rule 16b-3 | 12/24/2025 |
9 | Targets Report Why retail investors favor Cellectar Biosciences Inc stock - Market Growth Review Accurate EntryExit Alerts - moha.gov.vn | 01/02/2026 |
10 | Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - marketscreen... | 01/12/2026 |
11 | Cellectar Biosciences Outlines Key Development Milestones for 2026 - AD HOC NEWS | 01/29/2026 |
| Begin Period Cash Flow | 9.6 M | |
| Total Cashflows From Investing Activities | -104.2 K |
Cellectar | Build AI portfolio with Cellectar Stock |
Cellectar Biosciences Relative Risk vs. Return Landscape
If you would invest 330.00 in Cellectar Biosciences on November 1, 2025 and sell it today you would lose (6.00) from holding Cellectar Biosciences or give up 1.82% of portfolio value over 90 days. Cellectar Biosciences is currently generating 0.177% in daily expected returns and assumes 6.5428% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Cellectar, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cellectar Biosciences Target Price Odds to finish over Current Price
The tendency of Cellectar Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.24 | 90 days | 3.24 | about 59.87 |
Based on a normal probability distribution, the odds of Cellectar Biosciences to move above the current price in 90 days from now is about 59.87 (This Cellectar Biosciences probability density function shows the probability of Cellectar Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.08 suggesting Cellectar Biosciences market returns are sensitive to returns on the market. As the market goes up or down, Cellectar Biosciences is expected to follow. Additionally Cellectar Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Cellectar Biosciences Price Density |
| Price |
Predictive Modules for Cellectar Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cellectar Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cellectar Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cellectar Biosciences is not an exception. The market had few large corrections towards the Cellectar Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cellectar Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cellectar Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.18 | |
β | Beta against Dow Jones | 1.08 | |
σ | Overall volatility | 0.40 | |
Ir | Information ratio | -0.03 |
Cellectar Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cellectar Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cellectar Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cellectar Biosciences had very high historical volatility over the last 90 days | |
| Cellectar Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (44.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cellectar Biosciences currently holds about 24.81 M in cash with (47.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from telegraph.co.uk: Gregory Gregoriadis, scientist whose work on liposomes helped develop Covid-19 vaccines obituary |
Cellectar Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cellectar Stock often depends not only on the future outlook of the current and potential Cellectar Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cellectar Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.2 M | |
| Cash And Short Term Investments | 23.3 M |
Cellectar Biosciences Fundamentals Growth
Cellectar Stock prices reflect investors' perceptions of the future prospects and financial health of Cellectar Biosciences, and Cellectar Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellectar Stock performance.
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 2.39 M | ||||
| Shares Outstanding | 4.24 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 1.87 X | ||||
| EBITDA | (51.49 M) | ||||
| Net Income | (44.58 M) | ||||
| Cash And Equivalents | 24.81 M | ||||
| Cash Per Share | 4.06 X | ||||
| Total Debt | 494 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.51 X | ||||
| Book Value Per Share | 2.34 X | ||||
| Cash Flow From Operations | (47.58 M) | ||||
| Earnings Per Share | (8.07) X | ||||
| Market Capitalization | 13.74 M | ||||
| Total Asset | 25.47 M | ||||
| Retained Earnings | (247.34 M) | ||||
| Working Capital | 14.86 M | ||||
| Current Asset | 8.14 M | ||||
| Current Liabilities | 1.39 M | ||||
About Cellectar Biosciences Performance
By analyzing Cellectar Biosciences' fundamental ratios, stakeholders can gain valuable insights into Cellectar Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cellectar Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cellectar Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.58) | (1.65) | |
| Return On Capital Employed | (3.70) | (3.52) | |
| Return On Assets | (1.58) | (1.65) | |
| Return On Equity | (3.59) | (3.41) |
Things to note about Cellectar Biosciences performance evaluation
Checking the ongoing alerts about Cellectar Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellectar Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellectar Biosciences had very high historical volatility over the last 90 days | |
| Cellectar Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (44.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cellectar Biosciences currently holds about 24.81 M in cash with (47.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from telegraph.co.uk: Gregory Gregoriadis, scientist whose work on liposomes helped develop Covid-19 vaccines obituary |
- Analyzing Cellectar Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellectar Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Cellectar Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellectar Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellectar Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellectar Biosciences' stock. These opinions can provide insight into Cellectar Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cellectar Stock analysis
When running Cellectar Biosciences' price analysis, check to measure Cellectar Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectar Biosciences is operating at the current time. Most of Cellectar Biosciences' value examination focuses on studying past and present price action to predict the probability of Cellectar Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectar Biosciences' price. Additionally, you may evaluate how the addition of Cellectar Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |